JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Search

West Pharmaceutical Services Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

282.22 1.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

281.52

Max

283.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

8.2M

140M

Pardavimai

38M

804M

P/E

Sektoriaus vid.

44.052

37.003

Pelnas, tenkantis vienai akcijai

1.96

Dividendų pajamingumas

0.28

Pelno marža

17.406

Darbuotojai

10,600

EBITDA

17M

215M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+23.24% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.28%

2.25%

Kitas dividendų mokėjimo data

2025-11-19

Kita Ex Dividend data

2025-11-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

21B

Ankstesnė atidarymo kaina

280.86

Ankstesnė uždarymo kaina

282.22

Naujienos nuotaikos

By Acuity

50%

50%

142 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

West Pharmaceutical Services Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-02 22:13; UTC

Uždarbis

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2025-11-02 21:23; UTC

Uždarbis

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2025-11-02 23:43; UTC

Rinkos pokalbiai

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2025-11-02 23:34; UTC

Rinkos pokalbiai

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2025-11-02 21:00; UTC

Uždarbis

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2025-11-02 21:00; UTC

Uždarbis

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2025-11-02 21:00; UTC

Uždarbis

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2025-11-02 20:55; UTC

Uždarbis

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2025-11-02 20:55; UTC

Uždarbis

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2025-11-02 20:55; UTC

Uždarbis

Westpac FY Business Lending Up 15% on Year>WBC.AU

2025-11-02 20:46; UTC

Uždarbis

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2025-11-02 20:46; UTC

Uždarbis

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2025-11-02 20:45; UTC

Uždarbis

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2025-11-02 20:44; UTC

Uždarbis

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2025-11-02 20:43; UTC

Uždarbis

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2025-11-02 20:42; UTC

Uždarbis

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2025-11-02 20:41; UTC

Uždarbis

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2025-11-02 20:40; UTC

Uždarbis

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2025-11-02 20:39; UTC

Uždarbis

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2025-11-02 20:37; UTC

Uždarbis

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2025-11-02 20:37; UTC

Uždarbis

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2025-11-02 20:37; UTC

Uždarbis

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2025-11-02 20:36; UTC

Uždarbis

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2025-11-02 20:35; UTC

Uždarbis

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2025-11-02 20:35; UTC

Uždarbis

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2025-11-02 20:35; UTC

Uždarbis

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2025-11-02 20:34; UTC

Uždarbis

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2025-11-02 20:33; UTC

Uždarbis

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2025-11-02 14:27; UTC

Uždarbis

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2025-11-02 14:25; UTC

Uždarbis

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Akcijų palyginimas

Kainos pokytis

West Pharmaceutical Services Inc Prognozė

Kainos tikslas

By TipRanks

23.24% į viršų

12 mėnesių prognozė

Vidutinis 347.63 USD  23.24%

Aukščiausias 375 USD

Žemiausias 311 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines West Pharmaceutical Services Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

213.26 / 219.27Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

142 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat